Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology/Complications

Electrocardiographic Left Ventricular Hypertrophy in Type 1 Diabetes

Prevalence and relation to coronary heart disease and cardiovascular risk factors: the Eurodiab IDDM Complications Study

  1. Sara Giunti, MD1,
  2. Graziella Bruno, MD1,
  3. Massimo Veglio, MD2,
  4. Gabriella Gruden, MD, PHD1,
  5. David J. Webb, MSC3,
  6. Shona Livingstone, MSC3,
  7. Nish Chaturvedi, MRCP, MD4,
  8. John H. Fuller, FRCP3,
  9. Paolo Cavallo Perin, MD1 and
  10. the EURODIAB IDDM Complications Study Group
  1. 1Department of Internal Medicine, University of Turin, Turin, Italy
  2. 2Ospedale Evangelico Valdese, Turin, Italy
  3. 3Department of Epidemiology and Public Health, University College London, London, U.K.
  4. 4International Centre for Circulatory Health and National Heart and Lung Institute, Imperial College, London, U.K.
  1. Address correspondence and reprint requests to Dr. Sara Giunti, Department of Internal Medicine, University of Turin, 14, C.so A.M. Dogliotti, I-10126, Torino, Italy. E-mail: sara_giunti{at}katamail.com
Diabetes Care 2005 Sep; 28(9): 2255-2257. https://doi.org/10.2337/diacare.28.9.2255
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Prevalence and relation to coronary heart disease and cardiovascular risk factors: the Eurodiab IDDM Complications Study

  • CHD, coronary heart disease
  • ECG, electrocardiogram
  • GDR, glucose disposal rate
  • LVH, left ventricular hypertrophy
  • sBP, systolic blood pressure
  • WHR, waist-to-hip ratio

In the general population, left ventricular hypertrophy (LVH), either defined by echocardiographic or electrocardiogram (ECG) criteria, is strongly predictive of cardiovascular events, independent of conventional risk factors (1–3).

Normotensive type 1 diabetic patients with nephropathy have an increase in left ventricular mass independent of blood pressure (4) and a decrease in diastolic function (5). In the general population, LVH causes electrical heterogeneity in the heart (6) and is associated with sudden cardiac death secondary to ventricular arrhythmias. Both QT interval duration (QTc) and dispersion (QTd) are affected by electrical heterogeneity and associated with sudden death (7).

The EURODIAB IDDM Complications Study is a cross-sectional clinic-based study of diabetes complications recruiting 3,250 type 1 European diabetic subjects (8) using standardized methods of data collection. We aimed to assess ECG-LVH prevalence and association with coronary heart disease (CHD), microvascular complications, QTc, and QTd in this large cohort.

RESEARCH DESIGN AND METHODS

Details of the subjects and the procedures of the EURODIAB study have been published elsewhere (8–13). To assess the role of insulin resistance, an estimated glucose disposal rate (GDR) was calculated as previously described (14). Metabolic syndrome was defined according to World Health Organization guidelines (15).

LVH was defined by ECG Cornell voltage-duration product [(RaVL + SV3) × QRS complex duration] >2,623 mm × ms in men and >1,558.7 mm × ms in women (16). Compared with echocardiography, these cutoff values give the best sensitivity with a specificity of 95% (16). ECG measurements were made with a ruler on the resting ECG tracings, available for 3,113 of 3,250 (95.8%) patients, and were expressed as the average of three determinations on consecutive QRS complexes. R wave amplitude in aVL and S wave depth in V3 were measured as the distance (in millimeters) from the isoelectric line of their zenith and nadir, respectively. QRS duration was measured from the beginning to the end of the QRS complex.

Logistic regression analysis was used to assess variables independently related to LVH. All continuous variables were categorized in quartiles of their distribution apart from age (15–29, 30–44, and >44 years) and albumin excretion rate (<20, 20–200, and >200 μg/min). Since estimated odds ratios (ORs) in the lower quartiles of the waist-to-hip ratio (WHR) were similar, in the final analysis they were aggregated as reference categories and compared with the upper quartile of WHR (≤0.88 vs. >0.88). All analyses were performed with Stata (Stata Release 7.0; Stata, College Station, TX).

RESULTS

Age and duration of diabetes were 32.7 ± 10.7 and 14.7 ± 9.3 years (means ± SD), respectively. ECG-LVH prevalence was 3.4% (95% CI 2.8–4.1) higher in women than in men (4.6 vs. 2.3%, OR 2.02 [95% CI 1.34–3.02]), even after adjustment for age, duration of diabetes, BMI, systolic blood pressure (sBP) and diastolic blood pressure, and physical activity (2.40 [1.55–3.70]).

Subjects with ECG-LVH compared with those without had significantly higher sBP (129.3 ± 25.9 vs. 121.0 ± 17.4 mmHg, P = 0.001) and diastolic blood pressure (78.3 ± 12.8 vs. 75.4 ± 11.3 mmHg, P = 0.03), total cholesterol (5.55 ± 1.20 vs. 5.32 ± 1.14 mmol/l, P = 0.05), and triglycerides (geometric mean 1.04 vs. 0.93 and interquartile range 0.82–1.62 vs. 0.68–1.32, P = 0.003). Age and BMI were slightly higher in subjects with ECG-LVH, whereas HbA1c values were similar in the two groups.

Age- and sex-adjusted risks of LVH were higher in subjects with CHD (OR 2.85 [95% CI 1.75–4.64]), hypertension (1.69 [1.10–2.61]), macroalbuminuria (2.21 [1.25–3.93]), and prolonged QTc (3.24 [2.13–4.94]). No increased ORs were observed in subjects with retinopathy, neuropathy, and microalbuminuria.

A tendency toward decreasing risk of LVH with increasing estimated GDR values was evident (OR 0.61 [95% CI 0.34–1.08] in the upper versus lower quartiles). Frequencies of subjects with ECG-LVH were similar in subjects with and without metabolic syndrome (4.0 vs. 3.3%, P = 0.43; age- and sex-adjusted OR 1.24 [0.75–2.04]).

In multivariate logistic regression analysis (Table 1), variables independently related to ECG-LVH after adjustment for age, sex, and diabetes duration were CHD, QTc, macroalbuminuria, and sBP. When quartiles of triglycerides were included in this model, the association between ECG-LVH and macroalbuminuria was reduced from 2.66 to 0.87, whereas ORs for triglycerides were 3.47 and 2.42 in the upper quartiles. WHR contributed to the final model with OR 2.20 in subjects with WHR >0.88. The contribution of estimated GDR to models was not significant, even after removal of variables associated with insulin resistance syndrome (sBP, WHR, and triglycerides). Results were similar even when restricting analyses to either subjects without CHD or with normoalbuminuria.

CONCLUSIONS

This study shows a twofold-higher risk of ECG-LVH in women than in men and the association of ECG-LVH with triglycerides, WHR and sBP, QTc, and CHD.

Overall prevalence of ECG-LVH was 3.4%, three times greater than that reported in the general population of similar age using ECG criteria (3) and twofold-higher in women than in men, independent of known risk factors (sBP, BMI, and physical activity). Similarly, we recently observed a threefold-higher ECG-LVH risk in type 2 diabetic women from the Casale Monferrato Study (17).

Risk of ECG-LVH was strongly and independently associated with higher triglyceride levels and with WHR >0.88. This is consistent with previous studies suggesting the association between insulin resistance and LVH in both hypertensive subjects (18) and type 1 diabetic patients with nephropathy (4,5) and extends previous observations to normoalbuminuric subjects. Higher risk in macroalbuminuric patients was mainly explained by triglycerides, suggesting insulin resistance as the factor underlying LVH and overt diabetic nephropathy. We found decreasing age- and sex-adjusted ORs of ECG-LVH across quartiles of GDR; however, this finding was not confirmed in multivariate analysis, probably due to misclassification bias of this estimate, which determines a bias toward the null value of significance test. This study provides the first evidence of an independent association between ECG-LVH and CHD in type 1 diabetic patients and extends to them findings obtained in the general population by the Framingham Study (2). ECG-LVH prevalence was independently associated with QTc, consistent with the results from the Insulin Resistance Atherosclerosis Study (19). In addition, this result, together with previous reports showing that QTc is associated with both blood pressure (12,19) and sudden death (7), supports the hypothesis that LVH is the factor linking blood pressure to QTc prolongation and increased cardiovascular mortality (19).

View this table:
  • View inline
  • View popup
Table 1—

Results of unconditional regression analysis of variables independently associated with ECG-LVH in the EURODIAB cohort*

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted May 31, 2005.
    • Received May 19, 2005.
  • DIABETES CARE

References

  1. ↵
    Sundstrom J, Lind L, Arnlov J, Zethelius B, Andren B, Lithell HO: Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 103: 2346–2351, 2001
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Kannel WB: Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens 9: S3–S9, 1991
    OpenUrl
  3. ↵
    Brown DW, Giles WH, Croft JB: Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 140: 848–856, 2000
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Sato A, Tarnow L, Parving HH: Increased left ventricular mass in normotensive type 1 diabetic patients with diabetic nephropathy. Diabetes Care 21: 1534–1539, 1998
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Sato A, Tarnow L, Parving HH: Prevalence of left ventricular hypertrophy in type 1 diabetic patients with diabetic nephropathy. Diabetologia 42: 76–80, 1999
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Wolk R, Cobbe SM, Hicks MN, Kane KA: Functional, structural and dynamic bases of electrical heterogeneity in healthy and diseased cardiac muscle: implications for arrhythmogenesis and antiarrhythmic drug therapy. Pharmacol Therapeutics 84: 207–231, 1999
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Schouten EG, Dekker JM, Meppelimk P, Kolk FJ, Vanderbroucke JP, Pool J: QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 84: 1516–1523, 1991
    OpenUrlAbstract/FREE Full Text
  8. ↵
    The EURODIAB IDDM Complication Study Group: Microvascular and acute complications in insulin dependent diabetes mellitus: the EURODIAB IDDM Complication Study. Diabetologia 37: 278–285, 1994
    OpenUrlCrossRefPubMedWeb of Science
  9. Aldington SJ, Kohner EM, Meuer S, Sjolie A-K, the EURODIAB IDDM Complication Study Group: Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complication Study. Diabetologia 38: 437–444, 1995
    OpenUrlPubMedWeb of Science
  10. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 39: 1377–1384, 1996
    OpenUrlCrossRefPubMedWeb of Science
  11. Koivisto VA, Stevens LK, Mattock M, Ebeling P, Muggeo M, Stephenson J, Idzior-Walus B: Cardiovascular disease and its risk factors in IDDM in Europe. Diabetes Care 19: 689–697, 1996
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Veglio M, Borra M, Stevens LK, Fuller JH, Perin PC: The relation between QTc interval prolongation and diabetic complications: the EURODIAB IDDM Complication Study Group. Diabetologia 42: 68–75, 1999
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Veglio M, Giunti S, Stevens LK, Fuller JH, Perin PC, the EURODIAB IDDM Complications Study Group: Prevalence of QT interval dispersion in type 1 diabetes and its relation with cardiac ischemia. Diabetes Care 25: 702–707, 2002
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ: Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49: 626–632, 2000
    OpenUrlAbstract
  15. ↵
    Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–553, 1998
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Norman JE, Levy D: Improved electrocardiographic detection of echocardiographic left ventricular hypertrophy: results of a correlated data base approach. J Am Coll Cardiol 26: 1022–1029, 1995
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Bruno G, Giunti S, Bargero G, Ferrero S, Pagano G, Perin PC: Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in type 2 diabetes: the Casale Monferrato Study. Diabet Med 21: 823–828, 2004
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Lind L, Andersson PE, Andren B, Hanni A, Lithell HO: Left ventricular hypertrophy in hypertension is associated with the insulin resistance metabolic syndrome. Hypertension 13: 433–438, 1995
  19. ↵
    Festa A, D’Agostino R, Rautaharju P, Mykkänen L, Haffner SM: Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects. Am J Cardiol 86: 1117–1122, 2000
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 28 (9)

In this Issue

September 2005, 28(9)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Electrocardiographic Left Ventricular Hypertrophy in Type 1 Diabetes
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Electrocardiographic Left Ventricular Hypertrophy in Type 1 Diabetes
Sara Giunti, Graziella Bruno, Massimo Veglio, Gabriella Gruden, David J. Webb, Shona Livingstone, Nish Chaturvedi, John H. Fuller, Paolo Cavallo Perin
Diabetes Care Sep 2005, 28 (9) 2255-2257; DOI: 10.2337/diacare.28.9.2255

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Electrocardiographic Left Ventricular Hypertrophy in Type 1 Diabetes
Sara Giunti, Graziella Bruno, Massimo Veglio, Gabriella Gruden, David J. Webb, Shona Livingstone, Nish Chaturvedi, John H. Fuller, Paolo Cavallo Perin
Diabetes Care Sep 2005, 28 (9) 2255-2257; DOI: 10.2337/diacare.28.9.2255
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort
  • Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
  • Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes
Show more Pathophysiology/Complications

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.